title: A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.
abstract: In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line strategy. We report a single institutional experience mobilizing HSCs using four different approaches in lymphoma patients. We prospectively collected mobilization outcomes on patients planned to undergo auto-HCT at Ohio State University. We report results of first mobilization attempts for all relapsed or refractory lymphoma patients between 2008 and 2014. We identified 255 lymphoma patients who underwent mobilization for planned auto-HCT. The 255 lymphoma patients underwent the following front line mobilization strategies: 95 (37%) G-CSF alone, 38 (15%) chemomobilization (G-CSF+chemotherapy), 97 (38%) preemptive day 4 plerixafor, and 25 (10%) rescue day 5 plerixafor. As expected, there were significant differences between cohorts including age, comorbidity indices, histology, and amount of prior chemotherapy. After controlling for differences between groups, the odds of collecting 2 × 106/kg HSCs on the first day of collection and 5 × 106/kg HSCs in total was the highest in the cohort undergoing chemomobilization. In conclusion, our experience highlights the effectiveness of chemomobilization.
authors.affiliation: Division of Hematology, University of Colorado, Aurora, CO, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Haverkos
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: P
authors.initials: P
authors.lastname: Elder
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: L
authors.initials: L
authors.lastname: O'Donnell
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: D
authors.initials: D
authors.lastname: Scholl
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: B
authors.initials: B
authors.lastname: Whittaker
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: S
authors.initials: S
authors.lastname: Vasu
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: S
authors.initials: S
authors.lastname: Penza
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Andritsos
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Devine
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Jaglowski
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001596:Benzylamines; D002452:Cell Count; D000080027:Cyclams; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods* / Q000592:standards; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor